Skip to content

A study comparing the efficacy and safety of two anesthetic drugs etomidate and thiopentone used for electroconvulsive therapy under general anesthesia.

A comparative study of etomidate versus thiopentone for modified electroconvulsive therapy - NIL

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
CTRI
Registry ID
CTRI/2024/03/063890
Enrollment
34
Registered
2024-03-08
Start date
Unknown
Completion date
Unknown
Last updated
2025-08-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: F333- Major depressive disorder, recurrent, severe with psychotic symptoms Health Condition 2: F339- Major depressive disorder, recurrent, unspecified Health Condition 3: F315- Bipolar disorder, current episodedepressed, severe, with psychotic features

Interventions

Intervention1: Etomidate: Patients will receive intravenous etomidate(aqueous) 0.3 mg/Kg for General Anesthesia. Total procedure duration 30 mins. Control Intervention1: Thiopentone: Patients will r

Sponsors

Institute of Neurosciences Kolkata
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: i) Patients between 18 to 65 years of age posted for modified electroconvulsive therapy. ii) ASA1,2. iii) Either sex

Exclusion criteria

Exclusion criteria: i)Patients with a history of adverse reactions to either thiopentone or etomidate, ii) Patients with a history of cardiovascular, respiratory, neurological disease or electrolyte imbalance iii)Severe arterial hypertension iv)ASA 3,4.

Design outcomes

Primary

MeasureTime frame
Duration of seizure activityTimepoint: Onset of visible contractions to end of visible contractions

Secondary

MeasureTime frame
Cardiovascular and respiratory parameters (heart rate, blood pressure, oxygen saturation) Timepoint: Basal, After induction and 1 min, 2 min, 3 min, 5 min, 10 min, 20 min, and 30 min following MECT;Time to recovery of consciousness and orientationTimepoint: N/A;Adverse effects such as nausea, vomiting, headache, and myoclonusTimepoint: Anytime in the first 12 hours after ECT.

Countries

India

Contacts

Public ContactBibhukalyani Das

Institute of Neurosciences Kolkata

bibhukalyanidas@gmail.com9836000519

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026